[18F]FES PET/CT in Endocrine Refractory Breast Cancer
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer
Sponsor: University of Pennsylvania
A PHASE2 clinical study on Breast Neoplasm and Estrogen Receptor Positive Breast Cancer, this trial is completed. The trial is conducted by University of Pennsylvania and has accumulated 16 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Dec 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .